Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GPR17 | Q13304 | 4/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | THRA | P10827 | 2/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | PPARD | Q03181 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21346723 | 0.82 | RXRA (0.48) | FFAR1FFAR4POLB | |
| SCHEMBL14793792 | 0.82 | S1PR1 (0.46) | FFAR1FFAR4LMNAL3MBTL1THRA | |
| SCHEMBL14793783 | 0.81 | CNR2 (0.47) | FFAR1FFAR4LMNAL3MBTL1THRA | |
| SCHEMBL27088425 | 0.81 | TSHR (0.66) | GPR17THRATHRBTSHRPLA2G4B | |
| SCHEMBL20235359 | 0.79 | L3MBTL1 (0.63) | FFAR1LMNAL3MBTL1GPR17PPARG | |
| SCHEMBL27517041 | 0.79 | PTPN11 (0.50) | GPR17THRATHRBPLA2G4B | |
| SCHEMBL21347353 | 0.79 | RXRA (0.50) | FFAR1FFAR4POLB | |
| SCHEMBL15876231 | 0.79 | FFAR1 (0.62) | FFAR1FFAR4THRATHRB | |
| SCHEMBL6301903 | 0.79 | KDM4E (0.47) | FFAR1FFAR4L3MBTL1THRATHRB | |
| SCHEMBL14793744 | 0.78 | L3MBTL1 (0.43) | FFAR1FFAR4L3MBTL1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2757093-B1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-12-07 | — | — | EP | disclosed |
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
| EP-2757093-A1 | GUANIDINOBENZOIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013039187-A1 | GUANIDINOBENZOIC ACID COMPOUND | アステラス製薬株式会社 (JP) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | SERPINB1, REN, SPINT2 | FFAR1 1978/4885FFAR4 3145/4885LMNA 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.